Vancouver, Canada) announced that the company has broadened its strategic alliance with Baxter Healthcare Corporation, granting Baxter the right to manufacture the surgical sealant product, CoSeal, and the surgical anti-adhesive product, Adhibit.
On February 25, 2003, Angiotech announced a strategic alliance entitling Baxter to worldwide (excluding Japan and certain other territories) sales, marketing and distribution rights for CoSeal and Adhibit.
This randomized, controlled, single-blind, clinical study was designed to evaluate the safety and efficacy of Adhibit
in reducing the incidence and severity of post-operative adhesions when applied immediately after the removal of uterine fibroids (myomectomy surgery).
It also has rights outside the US to Angiotech's Adhibit
non-drug-loaded surgical adhesion prevention product, as well as an option to obtain US rights for the product.
Untreated Patients Had 100% More Adhesions Than Patients Treated with Adhibit
So far this year, we have initiated pivotal studies in Europe for CoSeal(R) to test its safety and effectiveness as a pulmonary sealant and, in this quarter, we commenced an Adhibit
anti-adhesion trial in women undergoing fibroid removal.